Pacira BioSciences, Inc. (PCRX)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	501,894	473,757	468,224	470,045	475,987	466,796	459,408	456,932	467,528	477,676	453,959	435,517	401,278	374,341	368,761	321,619	309,893	307,163	302,053	326,256
Revenue (ttm)	US$ in thousands	700,966	694,957	690,310	681,754	674,978	665,689	669,229	669,173	666,823	654,062	614,318	580,497	541,533	510,887	500,649	440,564	427,221	421,097	408,298	435,397
Gross profit margin		71.60%	68.17%	67.83%	68.95%	70.52%	70.12%	68.65%	68.28%	70.11%	73.03%	73.90%	75.02%	74.10%	73.27%	73.66%	73.00%	72.54%	72.94%	73.98%	74.93%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $501,894K ÷ $700,966K
= 71.60%

Pacira BioSciences, Inc. has shown fluctuations in its gross profit margin over the specified period. The gross profit margin, which represents the percentage of revenue that exceeds the cost of goods sold, started at a high of 74.93% as of March 31, 2020, gradually declined to 68.28% by March 31, 2023. This declining trend might indicate challenges in maintaining profitability relative to costs during this period.

However, there was a slight increase in the gross profit margin to 71.60% by December 31, 2024, suggesting a potential improvement in managing production costs or an increase in product pricing. It is important to note that a higher gross profit margin generally indicates that a company is efficiently producing goods or services. Conversely, a decreasing margin could signal inefficiencies in production, pricing strategies, or increased costs.

Further analysis and comparison with industry peers would provide more insights into Pacira BioSciences, Inc.'s performance and competitiveness within its sector.